Royal London Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $338M | Sell |
1,342,483
-9,234
| -0.7% | -$1.99M | 0.62% | 22 |
|
|
2026
Q1 | $294M | Buy |
1,351,717
+36,849
| +3% | +$8.17M | 0.62% | 21 |
|
|
2025
Q4 | $300M | Buy |
1,314,868
+9,594
| +0.7% | +$2.19M | 0.63% | 20 |
|
|
2025
Q3 | $302M | Sell |
1,305,274
-8,784
| -0.7% | -$1.79M | 0.65% | 21 |
|
|
2025
Q2 | $244M | Sell |
1,314,058
-45,381
| -3% | -$8.43M | 0.56% | 27 |
|
|
2025
Q1 | $285M | Buy |
1,359,439
+54,217
| +4% | +$10.5M | 0.67% | 24 |
|
|
2024
Q4 | $232M | Sell |
1,305,222
-66,066
| -5% | -$12.1M | 0.57% | 30 |
|
|
2024
Q3 | $271M | Buy |
1,371,288
+12,248
| +0.9% | +$2.29M | 0.67% | 24 |
|
|
2024
Q2 | $233M | Sell |
1,359,040
-110,764
| -8% | -$18.3M | 0.6% | 32 |
|
|
2024
Q1 | $268M | Buy |
1,469,804
+94,958
| +7% | +$16.4M | 0.67% | 29 |
|
|
2023
Q4 | $213M | Buy |
1,374,846
+93,443
| +7% | +$13.6M | 0.61% | 32 |
|
|
2023
Q3 | $191M | Buy |
1,281,403
+92,201
| +8% | +$13.5M | 0.62% | 31 |
|
|
2023
Q2 | $160M | Buy |
1,189,202
+193,094
| +19% | +$28.3M | 0.52% | 39 |
|
|
2023
Q1 | $159M | Buy |
996,108
+69,437
| +7% | +$10.6M | 0.64% | 34 |
|
|
2022
Q4 | $150M | Buy |
926,671
+19,534
| +2% | +$3M | 0.67% | 30 |
|
|
2022
Q3 | $122M | Sell |
907,137
-47,868
| -5% | -$6.87M | 0.62% | 38 |
|
|
2022
Q2 | $147M | Sell |
955,005
-3,106
| -0.3% | -$475K | 0.68% | 36 |
|
|
2022
Q1 | $155M | Buy |
958,111
+73,637
| +8% | +$10.7M | 0.61% | 36 |
|
|
2021
Q4 | $120M | Sell |
884,474
-43,115
| -5% | -$5.09M | 0.45% | 48 |
|
|
2021
Q3 | $100M | Sell |
927,589
-19,163
| -2% | -$2.19M | 0.41% | 52 |
|
|
2021
Q2 | $107M | Sell |
946,752
-26,631
| -3% | -$3M | 0.44% | 46 |
|
|
2021
Q1 | $105M | Buy |
973,383
+24,070
| +3% | +$2.57M | 0.48% | 47 |
|
|
2020
Q4 | $102M | Buy |
949,313
+2,700
| +0.3% | +$259K | 0.53% | 41 |
|
|
2020
Q3 | $82.2M | Buy |
946,613
+18,521
| +2% | +$1.74M | 0.5% | 43 |
|
|
2020
Q2 | $89.5M | Buy |
928,092
+85,373
| +10% | +$7.52M | 0.63% | 30 |
|
|
2020
Q1 | $63.4M | Buy |
842,719
+10,763
| +1% | +$917K | 0.51% | 41 |
|
|
2019
Q4 | $73.6M | Buy |
831,956
+17,052
| +2% | +$1.42M | 0.51% | 38 |
|
|
2019
Q3 | $61.7M | Sell |
814,904
-6,295
| -0.8% | -$432K | 0.47% | 49 |
|
|
2019
Q2 | $59.7M | Sell |
821,199
-5,925
| -0.7% | -$466K | 0.56% | 44 |
|
|
2019
Q1 | $66.7M | Buy |
827,124
+27,428
| +3% | +$2.24M | 0.52% | 40 |
|
|
2018
Q4 | $72.9M | Buy |
799,696
+153,773
| +24% | +$13.5M | 0.64% | 29 |
|
|
2018
Q3 | $61.1M | Sell |
645,923
-31,357
| -5% | -$2.97M | 0.63% | 33 |
|
|
2018
Q2 | $62.8M | Buy |
+677,280
| New | +$66.1M | 0.63% | 30 |
|
|
2016
Q2 | $34M | Sell |
548,532
-22,307,910
| -98% | -$1.36B | 0.55% | 42 |
|
|
2016
Q1 | $400K | Buy |
22,856,442
+22,237,269
| +3,591% | +$1.24B | 0.57% | 30 |
|
|
2015
Q4 | $37M | Buy |
619,173
+6,831
| +1% | +$393K | 0.57% | 38 |
|
|
2015
Q3 | $33.3M | Buy |
+612,342
| New | +$39.9M | 0.54% | 41 |
|
|
2014
Q4 | $335K | Buy |
505,982
+114,683
| +29% | +$7.23M | 0.63% | 37 |
|
|
2014
Q3 | $22.9M | Buy |
391,299
+19,315
| +5% | +$1.07M | 0.57% | 39 |
|
|
2014
Q2 | $19.4M | Buy |
371,984
+4,444
| +1% | +$233K | 0.44% | 49 |
|
|
2014
Q1 | $19.2M | Sell |
367,540
-10,033
| -3% | -$507K | 0.45% | 52 |
|
|
2013
Q4 | $19.2M | Buy |
377,573
+4,591
| +1% | +$226K | 0.49% | 45 |
|
|
2013
Q3 | $17.9M | Buy |
372,982
+12,540
| +3% | +$556K | 0.48% | 47 |
|
|
2013
Q2 | $15.5M | Buy |
+360,442
| New | +$15.8M | 0.45% | 49 |
|
Other funds holding ABBV
Royal London Asset Management's ABBV Position: Q2 2026 in Review
Royal London Asset Management reduced its AbbVie (ABBV) stake by 0.68% in Q2 2026, selling an estimated $1.99M and leaving 1,342,483 shares worth $338M. The position accounts for 0.62% of the portfolio, ranked #22.
Royal London Asset Management first reported a position in ABBV in Q2 2013 and has held it in 44 quarters since. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Royal London Asset Management held 1,342,483 shares of AbbVie worth $338M as of Q2 2026.
- Royal London Asset Management sold 9,234 AbbVie shares in Q2 2026, an estimated $1.99M.
- AbbVie made up 0.62% of Royal London Asset Management's portfolio in Q2 2026, its #22 holding.
- Royal London Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 44 quarters since.
- 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Royal London Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.